Crossref journal-article
Proceedings of the National Academy of Sciences
Proceedings of the National Academy of Sciences (341)
Abstract

The oncoproteins MDM2 and MDMX negatively regulate the activity and stability of the tumor suppressor protein p53—a cellular process initiated by MDM2 and/or MDMX binding to the N-terminal transactivation domain of p53. MDM2 and MDMX in many tumors confer p53 inactivation and tumor survival, and are important molecular targets for anticancer therapy. We screened a duodecimal peptide phage library against site-specifically biotinylated p53-binding domains of human MDM2 and MDMX chemically synthesized via native chemical ligation, and identified several peptide inhibitors of the p53-MDM2/MDMX interactions. The most potent inhibitor (TSFAEYWNLLSP), termed PMI, bound to MDM2 and MDMX at low nanomolar affinities—approximately 2 orders of magnitude stronger than the wild-type p53 peptide of the same length (ETFSDLWKLLPE). We solved the crystal structures of synthetic MDM2 and MDMX, both in complex with PMI, at 1.6 Å resolution. Comparative structural analysis identified an extensive, tightened intramolecular H-bonding network in bound PMI that contributed to its conformational stability, thus enhanced binding to the 2 oncogenic proteins. Importantly, the C-terminal residue Pro of PMI induced formation of a hydrophobic cleft in MDMX previously unseen in the structures of p53-bound MDM2 or MDMX. Our findings deciphered the structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX, shedding new light on structure-based rational design of different classes of p53 activators for potential therapeutic use.

Bibliography

Pazgier, M., Liu, M., Zou, G., Yuan, W., Li, C., Li, C., Li, J., Monbo, J., Zella, D., Tarasov, S. G., & Lu, W. (2009). Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proceedings of the National Academy of Sciences, 106(12), 4665–4670.

Authors 11
  1. Marzena Pazgier (first)
  2. Min Liu (additional)
  3. Guozhang Zou (additional)
  4. Weirong Yuan (additional)
  5. Changqing Li (additional)
  6. Chong Li (additional)
  7. Jing Li (additional)
  8. Juahdi Monbo (additional)
  9. Davide Zella (additional)
  10. Sergey G. Tarasov (additional)
  11. Wuyuan Lu (additional)
References 51 Referenced 346
  1. 10.1038/35042675
  2. 10.1038/nrm2147
  3. 10.1038/nrc864
  4. 10.1200/JCO.1998.16.9.3158
  5. 10.1038/nature05529
  6. 10.1038/nature05541
  7. 10.1016/j.cell.2006.12.007
  8. 10.1038/nrc2012
  9. 10.1242/jcs.03362
  10. 10.1016/S0014-5793(97)01480-4
  11. 10.1128/MCB.20.3.1001-1007.2000
  12. 10.1002/j.1460-2075.1996.tb00919.x
  13. 10.1038/387299a0
  14. 10.1038/387296a0
  15. 10.1016/j.ccr.2006.03.014
  16. 10.1073/pnas.0508476103
  17. 10.1128/MCB.23.15.5113-5121.2003
  18. 10.1038/sj.emboj.7600145
  19. 10.1074/jbc.M213034200
  20. 10.1074/jbc.M308295200
  21. 10.1002/bip.20741
  22. 10.1073/pnas.0708917105
  23. 10.1126/science.1092472
  24. 10.1158/0008-5472.CAN-07-1140
  25. 10.1126/science.274.5289.948
  26. 10.1021/ja063102j
  27. 10.1021/jm049137g
  28. 10.1002/cbic.200500452
  29. GM Popowicz, et al., Molecular Basis for the Inhibition of p53 by Mdmx. Cell Cycle, pp. 6 (2007). / Cell Cycle / Molecular Basis for the Inhibition of p53 by Mdmx by Popowicz GM (2007)
  30. 10.1006/abbi.2000.1998
  31. 10.1016/S0022-2836(02)00852-5
  32. 10.1006/jmbi.1997.1078
  33. 10.1101/gad.8.10.1235
  34. SM Picksley, B Vojtesek, A Sparks, DP Lane, Immunochemical analysis of the interaction of p53 with MDM2—fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 9, 2523–2529 (1994). / Oncogene / Immunochemical analysis of the interaction of p53 with MDM2—fine mapping of the MDM2 binding site on p53 using synthetic peptides by Picksley SM (1994)
  35. 10.1002/bip.360221211
  36. V Bottger, et al., Identification of novel mdm2 binding peptides by phage display. Oncogene 13, 2141–2147 (1996). / Oncogene / Identification of novel mdm2 binding peptides by phage display by Bottger V (1996)
  37. 10.1146/annurev.biochem.69.1.923
  38. 10.1126/science.7973629
  39. 10.1021/ja990935j
  40. 10.1021/bi060309g
  41. 10.1021/ja804289g
  42. E Vives, J Schmidt, A Pelegrin, Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 1786, 126–138 (2008). / Biochim Biophys Acta / Cell-penetrating and cell-targeting peptides in drug delivery by Vives E (2008)
  43. 10.1021/ja8042036
  44. 10.1002/cbic.200500324
  45. 10.4161/cc.6365
  46. 10.1002/pro.5560041120
  47. 10.1107/S0907444903028956
  48. 10.1107/S0907444996012255
  49. 10.1107/S0907444904019158
  50. 10.1016/j.jmb.2008.11.043
  51. 10.1074/jbc.M809096200
Dates
Type When
Created 16 years, 5 months ago (March 2, 2009, 9:43 p.m.)
Deposited 3 years, 4 months ago (April 12, 2022, 5:35 p.m.)
Indexed 2 days, 21 hours ago (Aug. 22, 2025, 12:48 a.m.)
Issued 16 years, 5 months ago (March 24, 2009)
Published 16 years, 5 months ago (March 24, 2009)
Published Online 16 years, 5 months ago (March 24, 2009)
Published Print 16 years, 5 months ago (March 24, 2009)
Funders 0

None

@article{Pazgier_2009, title={Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX}, volume={106}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.0900947106}, DOI={10.1073/pnas.0900947106}, number={12}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Pazgier, Marzena and Liu, Min and Zou, Guozhang and Yuan, Weirong and Li, Changqing and Li, Chong and Li, Jing and Monbo, Juahdi and Zella, Davide and Tarasov, Sergey G. and Lu, Wuyuan}, year={2009}, month=mar, pages={4665–4670} }